BioLine Rx Ltd (FRA:YP2)

Q4 2024 BioLine RX Ltd Earnings Call Transcript

Mar 31, 2025 / 12:30 PM GMT

Release Date Price: €2.98

Transcript

Key Points

Positve

BioLine Rx Ltd (BLRX) executed a significant licensing agreement with AirMed Limited, providing a $10 million upfront payment and potential commercial milestones of $87 million.
The company received a $9 million equity investment from High Bridge Capital, strengthening its financial position.
The licensing agreement allows BioLine Rx Ltd (BLRX) to reduce its cash burn significantly, extending its cash runway into 2026.
BioLine Rx Ltd (BLRX) plans to focus on drug development in oncology and rare diseases, leveraging its expertise in complex drug development.
The company achieved a 10% market share milestone for its stem cell mobilization agent, Effexta, in the US market.

Negative

BioLine Rx Ltd (BLRX) is shutting down its US commercial operations, which may lead to transitional challenges.
The company faces uncertainties in the timing of revenue generation from its licensing agreements, particularly in the Asian market.
There is a potential risk of delays in clinical trial enrollments and data availability, with full enrollment anticipated by 2027.
BioLine Rx Ltd (BLRX) reported a net loss of $5.8 million for the third quarter of 2024, despite improvements from the previous year.
The company is reliant on partnerships for the advancement of its PDAC program, which may limit its control over the development process.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BLRX.TA - BioLine RX Ltd
Q4 2024 BioLine RX Ltd Earnings Call
Mar 31, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
For financial results conference call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question and answer session.

I would now like to turn over the call to John Lacey, head of investor relations and corporate communications. John, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Welcome everyone.

Thank you for joining us on our 3rd quarter of 2024 results conference call.

Earlier today we issued a press release, a copy of which is available

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.